Cooperative ProductionDecentralized Coordinationmedium
Regulated biosimilar buying coalition
Public purchasers, self-insured employers, clinics, and biosimilar manufacturers coordinate demand commitments around FDA-approved biosimilars and interchangeable biologics, using transparent formularies and outcomes reporting to pressure mature branded biologic economics.
Thesis
The market structure shifts from single-sponsor brand pricing toward coordinated buyer demand and multi-sponsor biosimilar supply, especially for mature biologics facing payer pressure.
Bitcoin / decentralization role
Decentralization matters through buyer coordination and transparent outcomes governance rather than Bitcoin. The core mechanism is a federated purchasing and evidence network that prevents any one payer, PBM, or sponsor from controlling the substitution pathway.
Coordination mechanism
Buyers commit covered lives and volume targets; clinics report switching outcomes; biosimilar suppliers bid against standardized quality and supply requirements; formularies update based on FDA status, availability, net cost, and patient outcomes.
Verification / trust model
FDA approval constrains product-quality claims, while claims data, adverse-event reporting, and third-party audits constrain false savings or fake fulfillment. The weak point is that rebate contracts and confidential net pricing can still obscure true economics.
Failure modes
- • Incumbent rebate contracts block formulary movement even when biosimilars are approved.
- • Patients and clinicians resist switching if real-world support or supply reliability is weak.
- • Coalition governance can be captured by large payers or distributors.
Adoption path
- • Start with mature inflammatory biologic categories where payer pressure is already visible.
- • Create transparent switching registries and procurement commitments among employers, public plans, and clinics.
- • Expand only after supply reliability, pharmacovigilance, and patient-support workflows match incumbent standards.
Decentralization fit
58.0/10
The concept decentralizes purchasing and evidence governance, but still relies on regulated manufacturers and conventional distribution.
Coordination credibility
66.0/10
FDA biosimilar and interchangeability pathways provide a real coordination anchor for payers and suppliers.
Implementation feasibility
54.0/10
The policy and data pieces are plausible, but payer contracting, physician trust, and patient support are hard operational problems.
Incumbent pressure
63.0/10
Enbrel's 2025 sales decline from lower net selling price shows that payer and access dynamics can already pressure the franchise.